Workflow
icon
Search documents
舜宇光学科技:2025年业务指引增长强劲,利润有望持续上扬-20250328
浦银国际· 2025-03-28 06:25
浦银国际研究 公司研究 | 科技行业 舜宇光学科技(2382.HK):2025 年业务 指引增长强劲,利润有望持续上扬 上调舜宇光学目标价至 88.9 港元,潜在升幅 18%,重申"买入"评级。 图表 1:盈利预测和财务指标(2023-2027E) | 人民币百万元 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营收 | 31,681 | 38,294 | 41,677 | 46,310 | 50,842 | | 营收同比增速 | (5%) | 21% | 9% | 11% | 10% | | 毛利率 | 14.5% | 18.3% | 19.3% | 19.8% | 20.2% | | 净利润 | 1,099 | 2,699 | 3,306 | 3,948 | 4,610 | | 净利润增速 | (54%) | 146% | 22% | 19% | 17% | | 目标 P/E (x) | 82.2 | 33.4 | 27.4 | 22.9 | 19.7 | E=浦银国际预测 资料来源:公司报告 ...
药明合联(02268):24年业绩略超预期,维持25年35%收入增速指引
浦银国际· 2025-03-26 07:16
药明合联(2268.HK):24 年业绩略超 预期,维持 25 年 35%收入增速指引 浦银国际研究 公司研究 | 医药行业 公司 2024 年业绩略超此前公布的正面盈利预告,2025 年收入预计将 实现 35%以上增速。重申"买入"评级,目标价为 50 港元。 阳景 首席医药分析师 Jing_yang@spdbi.com (852) 2808 6434 胡泽宇 CFA 医药分析师 ryan_hu@spdbi.com (852) 2808 6446 2025 年 3 月 26 日 | 评级 | | | --- | --- | | 目标价(港元) | 50.0 | | 潜在升幅/降幅 | +25% | | 目前股价(港元) | 40.0 | | 52 周内股价区间(港元) | 14.0-46.9 | | 总市值(百万港元) | 48,041 | | 近 3 月日均成交额(百万) | 194 | 市场预期区间 SPDBI目标价 目前价 市场预期区间 资料来源:Bloomberg、浦银国际 注:截至 2025 年 3 月 25 日收盘价 股价表现 HK$35.0 HK$40.0 HK$50.0 HK$50.0 35 ...
腾讯控股(00700):借AI东风,腾讯能否重回700?
浦银国际· 2025-03-20 11:06
浦银国际研究 公司研究 | 互联网行业 腾讯(700.HK):借 AI 东风,腾讯能否 重回 700? 业绩超预期,宣布派发股息及回购:公司 4Q24 收入人民币 1,725 亿 元,同比增长 11%,高于市场预期 2.3%;毛利率 52.6%,同比提升 3 个 百分点,各分部毛利率同比均有改善;调整后净利润为 553 亿元,同 比增长 30%,高于市场预期;调整后净利率 32.1%,4Q23 为 27.5%, 3Q24 为 35.8%。公司宣布派发每股股息 4.5 港元,在 2025 年至少回购 800 亿港元股份,两者约合 2.4%的股东回报。 本土游戏表现亮眼,预计 1Q25 保持强劲势头:4Q24 本土游戏收入同 比增长 23%至 332 亿元,增长强劲,好于我们预期,主要得益于去年 低基数以及旗舰游戏的健康表现。根据 Sensor Tower 数据监测,《王者 荣耀》在今年一季度目前表现依然亮眼,1 月和 2 月成为该游戏自 2021 年以来收入最高的两个月。国际游戏收入同比增长 15%至 160 亿元, 主要受《PUBG MOBILE》《荒野乱斗》等游戏推动。低基数效应在上半 年仍将持续,且递延收 ...
小米集团-W(01810):四季度业绩创历史新高,看好公司长期价值成长
浦银国际· 2025-03-20 11:05
浦银国际研究 公司研究 | 科技行业 小米集团(1810.HK):四季度业绩创 历史新高,看好公司长期价值成长 重申小米的"买入"评级,上调目标价至 75.0 港元,潜在升幅 29%。 首席科技分析师 tony_shen@spdbi.com (852) 2808 6435 黄佳琦 重申小米的"买入"评级:在 2024 年四季度,小米的收入、经调整 后净利润、经调整后核心业务净利润分别录得人民币 1,090 亿、83 亿、 90 亿元,均取得历史新高,增长强劲。这两年的经营表现充分体现 其公司战略方向和管理层执行力。小米人车家生态闭环,给予公司长 期增长空间。手机、新能源车、IoT 等业务板块均有望取得中国和全 球领先的位置。这将带来公司收入规模的增长和潜在利润的加速释放。 作为行业首推之一,当前小米市盈率为 42.1x,考虑其新能源车增长、 AI 战略定位和多业务板块龙头估值溢价,估值仍然具备上升空间。我 们对于小米长期的价值增长保持较为乐观的判断。 小米 2025 年展望:1)智能手机:我们预期今年出货量有望达 1.8 亿 部以上。受益于上游成本下行、高端化战略、中国国补等,手机毛利 率有改善空间。2)Io ...
安踏体育(02020):利润率短期扩张可能受限,但多品牌战略将持续驱动规模扩张
浦银国际· 2025-03-20 09:29
浦银国际研究 公司研究 | 消费行业 安踏(2020.HK):利润率短期扩张可能受 限,但多品牌战略将持续驱动规模扩张 展望 2025 年,尽管安踏的利润率可能继续面临较大的压力,但主力品 牌的收入规模有望稳步扩张,其他品牌的流水将维持高速增长,同时 Amer Sports 的收入贡献将大幅提升,助力公司 2025 年核心净利润维 持较高的增长。长期来看,多品牌战略有望持续驱动公司整体收入规 模的扩张。上调目标价至 118.8 港元,并维持"买入"评级。 林闻嘉 首席消费分析师 richard_lin@spdbi.com (852) 2808 6433 桑若楠,CFA 消费分析师 serena_sang@spdbi.com (852) 2808 6439 2025 年 3 月 20 日 评级 | 目标价(港元) | 118.8 | | --- | --- | | 潜在升幅/降幅 | +21.3% | | 目前股价(港元) | 97.9 | | 52 周内股价区间(港元) | 65.6-107.5 | | 总市值(百万港元) | 274,826 | | 近 3月日均成交额(百万港元) | 983.1 | | 注 ...
药明康德(02359):新签订单再提速、额外分红及A股回购推动股价上涨
浦银国际· 2025-03-19 07:31
Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 90 and RMB 93, indicating a potential upside of +38% and +45% respectively [3][5][9]. Core Insights - The acceleration in new order signings, along with an additional special dividend and A-share buyback, are the major positive surprises that have driven the company's stock price up [3][8]. - For 2024, the company achieved a revenue of RMB 39.24 billion, a decrease of 2.7% YoY, but a growth of 5.2% YoY when excluding COVID-19 commercialization projects [8][10]. - The company reported a Non-IFRS adjusted net profit of RMB 10.58 billion for 2024, down 2.5% YoY, with a net profit margin of 27% [8][10]. Revenue and Growth Drivers - The small molecule D&M revenue and TIDES business remain the main drivers of revenue growth, with TIDES revenue growing by 67.9% YoY and small molecule D&M revenue increasing by 16.1% YoY [3][8]. - The company expects TIDES business to maintain over 60% YoY revenue growth in 2025, with total revenue projected to reach RMB 41.5-43 billion, representing a 10%-15% YoY increase [8][9]. Financial Performance - In Q4 2024, the company achieved a revenue of RMB 11.54 billion, a 6.9% increase YoY, and a Non-IFRS adjusted net profit of RMB 3.24 billion, up 20.4% YoY [10][12]. - The company ended 2024 with a backlog of orders amounting to RMB 49.31 billion, a 47% increase YoY, indicating strong execution and international competitiveness [8][10]. Shareholder Returns - The company plans to distribute an additional special dividend of RMB 1 billion and conduct a RMB 1 billion A-share buyback in 2025, which is expected to positively impact stock performance [8][9]. - The management also announced a H-share incentive trust plan for 2025, with an allocation of HKD 1.5-2.5 billion, depending on revenue targets [8][9].
药明康德(603259):新签订单再提速、额外分红及A股回购推动股价上涨
浦银国际· 2025-03-19 02:44
Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 90 and RMB 93, indicating a potential upside of +38% and +45% respectively [3][5][9]. Core Insights - The acceleration in new order signings, along with an additional special dividend and A-share buyback, are the major positive surprises that have driven the company's stock price up [3][8]. - For 2024, the company achieved a revenue of RMB 39.24 billion, a decrease of 2.7% YoY, but a growth of 5.2% YoY when excluding COVID-19 commercialization projects [8][10]. - The company reported a Non-IFRS adjusted net profit of RMB 10.58 billion for 2024, down 2.5% YoY, with a net profit margin of 27% [8][10]. Revenue and Growth Drivers - The small molecule D&M revenue and TIDES business remain the main drivers of revenue growth, with TIDES revenue growing by 67.9% YoY [3][8]. - The company expects TIDES business to maintain over 60% YoY revenue growth in 2025, while small molecule D&M revenue is also projected to grow significantly [8][9]. Financial Performance - In Q4 2024, the company achieved a revenue of RMB 11.54 billion, representing a 6.9% YoY increase and a 10.3% QoQ increase [10][12]. - The adjusted Non-IFRS net profit for Q4 2024 was RMB 3.24 billion, up 20.4% YoY, with a net profit margin of 28.1% [10][12]. Future Guidance - For 2025, the company expects revenue from continuing operations to reach RMB 41.5-43 billion, representing a 10%-15% YoY growth [8][9]. - The company plans to distribute an additional special dividend of RMB 1 billion and conduct a RMB 1 billion A-share buyback in 2025 [8][9]. Market Position - The company ended 2024 with a backlog of orders amounting to RMB 49.31 billion, a 47% YoY increase, indicating strong execution capabilities and international competitiveness [8][9].
华润啤酒(00291):2025年业绩反转的确定性大于竞争对手,维持“买入”
浦银国际· 2025-03-19 02:39
Investment Rating - The report maintains a "Buy" rating for China Resources Beer (291.HK) with a target price of HKD 34.3, representing a potential upside of 20.4% from the current price of HKD 28.5 [3][6]. Core Views - The report highlights that the certainty of a performance turnaround in 2025 for China Resources Beer is greater than that of its competitors. The company is expected to achieve positive revenue growth in its beer business for the full year of 2025, supported by a strong start in the first two months of the year [6][10]. - The company's strategy of continuous premiumization is seen as more favorable compared to major competitors, with a projected sales volume decline of only 2.5% in 2024, which is less severe than that of its peers [6][10]. - The management's emphasis on the "Three Precision" strategy aims to streamline operations and reduce costs, which is expected to enhance profit margins in 2025 [6][10]. Financial Forecasts - Revenue projections for China Resources Beer are as follows: - 2023: RMB 38,932 million - 2024: RMB 38,635 million - 2025E: RMB 39,575 million - 2026E: RMB 40,526 million - 2027E: RMB 41,455 million - The year-on-year growth rates are 10.4%, -0.8%, 2.4%, 2.4%, and 2.3% respectively [2][10]. - Core net profit forecasts are: - 2023: RMB 5,259 million - 2024: RMB 4,766 million - 2025E: RMB 5,346 million - 2026E: RMB 5,758 million - 2027E: RMB 6,145 million - The year-on-year growth rates are 16.3%, -9.4%, 12.2%, 7.7%, and 6.7% respectively [2][10]. - Key financial ratios include: - PE ratios for 2025E: 16.1x - ROE for 2025E: 16.3% [2][10]. Market Positioning - The report indicates that China Resources Beer has a competitive edge over Budweiser APAC, with a stable management team and a sustainable strategic plan. The company is also expected to increase its dividend payout ratio from 40% in 2023 to 52% in 2024, with intentions to reach over 60% in the future [6][10].
丘钛科技(01478):聚焦收入高质量成长,利润大幅改善
浦银国际· 2025-03-18 12:29
Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 9.1, indicating a potential upside of 19% from the current price of HKD 7.63 [1][3]. Core Insights - The company focuses on high-quality revenue growth, strategically emphasizing high-end camera module projects, which is expected to lead to significant profit improvements in the second half of 2024 [7]. - The fundamental growth trend is anticipated to continue into 2025, driven by a doubling of shipments for mobile periscope modules, rapid growth in ultrasonic fingerprint recognition modules, and ongoing expansion in automotive and drone sectors [7]. - The company has shown strong performance in controlling expenses, resulting in a net profit increase of 168% year-on-year for 2024 [7]. Financial Forecasts - Revenue is projected to grow from RMB 12,531 million in 2023 to RMB 20,974 million by 2027, with a compound annual growth rate (CAGR) of approximately 8% [2]. - Net profit is expected to rise significantly from RMB 82 million in 2023 to RMB 667 million in 2027, reflecting a robust growth trajectory [2]. - The gross margin is forecasted to improve from 4.1% in 2023 to 7.0% in 2027, indicating enhanced profitability [2]. Performance Metrics - For the second half of 2024, the company anticipates a revenue of RMB 84.8 billion, a year-on-year increase of 20%, with a gross margin of 6.9% [7]. - The company expects that by 2025, at least 55% of mobile module shipments will be 32 million pixels or higher, with a significant increase in sales of fingerprint modules and automotive IoT modules [7]. - The average selling price of camera modules is projected to increase, contributing to overall revenue growth [7]. Valuation - The report employs a sum-of-the-parts valuation method, assigning target price-to-earnings (P/E) ratios of 15.0x for mobile camera modules, 18.0x for other camera modules, and 20.0x for fingerprint recognition modules, leading to a target price of HKD 9.1 [7][15].
2025小鹏汽车春季发布会:全新G6、G9正式登场
浦银国际· 2025-03-17 09:16
科技行业 | 行业追踪 2025 小鹏汽车春季发布会:全新 G6、G9 正式登场 3 月 13 日晚间,小鹏汽车举办春天里的第一场发布会, 2025 款小 鹏 G6 和 2025 款小鹏 G9 正式发布。这有望推动小鹏今年交付量 持续保持强劲增长动能。 小鹏 2024 年出海表现优异,短期交付量重回新势力第一。在发布 会上,小鹏汽车创始人何小鹏分享,小鹏汽车排名 2024 年中国新 势力品牌出口量第一。在出海出口方面,小鹏汽车还取得多项优 异成绩,包括中高端纯电出口中国品牌第一,首个达成欧洲万辆 交付的新势力品牌,欧洲十四国新势力品牌销量第一,小鹏 G9 北 欧市场中大型 SUV 销量第一,小鹏 G9 中东非市场中大型纯电 SUV 销量第一,小鹏 G6 中东非市场中型纯电 SUV 销量第一。2025 年, 小鹏汽车将进入 60 个国家和地区。并且,在 2025 年 1-2 月,小 鹏重返新势力交付量第一的位置。 在今年的第一场汽车发布会上,小鹏发布 2025 款 G6 和 G9,全系 标配图灵 AI 智驾。智驾功能不选装、不订阅、不付费。同时,G6 和 G9 全系标配 5C 电池,充电 10 分钟补能 450 ...